300 related articles for article (PubMed ID: 31191515)
21. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
22. B7H4 expression in tumor cells impairs CD8 T cell responses and tumor immunity.
Zhou L; Ruan M; Liu Y; Zhu Y; Fu D; Wu K; Zhang Q
Cancer Immunol Immunother; 2020 Feb; 69(2):163-174. PubMed ID: 31848656
[TBL] [Abstract][Full Text] [Related]
23. Tissue-resident memory T cells in breast cancer control and immunotherapy responses.
Byrne A; Savas P; Sant S; Li R; Virassamy B; Luen SJ; Beavis PA; Mackay LK; Neeson PJ; Loi S
Nat Rev Clin Oncol; 2020 Jun; 17(6):341-348. PubMed ID: 32112054
[TBL] [Abstract][Full Text] [Related]
24. To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors.
Mondino A; Manzo T
Front Immunol; 2020; 11():1915. PubMed ID: 32973794
[TBL] [Abstract][Full Text] [Related]
25. Metabolic Barriers to T Cell Function in Tumors.
Sugiura A; Rathmell JC
J Immunol; 2018 Jan; 200(2):400-407. PubMed ID: 29311381
[TBL] [Abstract][Full Text] [Related]
26. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.
Linette GP; Carreno BM
Curr Hematol Malig Rep; 2019 Aug; 14(4):286-291. PubMed ID: 31187421
[TBL] [Abstract][Full Text] [Related]
27. Tumor-resident memory T cells as a biomarker of the response to cancer immunotherapy.
Damei I; Trickovic T; Mami-Chouaib F; Corgnac S
Front Immunol; 2023; 14():1205984. PubMed ID: 37545498
[TBL] [Abstract][Full Text] [Related]
28. Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β
Overgaard NH; Principe DR; Schachtschneider KM; Jakobsen JT; Rund LA; Grippo PJ; Schook LB; Jungersen G
Front Immunol; 2018; 9():1301. PubMed ID: 29930558
[TBL] [Abstract][Full Text] [Related]
29. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
Rivadeneira DB; Delgoffe GM
Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
[TBL] [Abstract][Full Text] [Related]
30. Engineering T cells for cancer: our synthetic future.
Vonderheide RH; June CH
Immunol Rev; 2014 Jan; 257(1):7-13. PubMed ID: 24329786
[No Abstract] [Full Text] [Related]
31. Niches for the Long-Term Maintenance of Tissue-Resident Memory T Cells.
Takamura S
Front Immunol; 2018; 9():1214. PubMed ID: 29904388
[TBL] [Abstract][Full Text] [Related]
32. LIGHT May Improve Immune Checkpoint Blockade Response.
Cancer Discov; 2016 Jun; 6(6):OF9. PubMed ID: 27080334
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer.
Welters MJP; Ma W; Santegoets SJAM; Goedemans R; Ehsan I; Jordanova ES; van Ham VJ; van Unen V; Koning F; van Egmond SI; Charoentong P; Trajanoski Z; van der Velden LA; van der Burg SH
Clin Cancer Res; 2018 Feb; 24(3):634-647. PubMed ID: 29018052
[No Abstract] [Full Text] [Related]
34. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
[TBL] [Abstract][Full Text] [Related]
35. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8
Enamorado M; Iborra S; Priego E; Cueto FJ; Quintana JA; Martínez-Cano S; Mejías-Pérez E; Esteban M; Melero I; Hidalgo A; Sancho D
Nat Commun; 2017 Jul; 8():16073. PubMed ID: 28714465
[TBL] [Abstract][Full Text] [Related]
36. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
Bao R; Stapor D; Luke JJ
Genome Med; 2020 Oct; 12(1):90. PubMed ID: 33106165
[TBL] [Abstract][Full Text] [Related]
37. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
38. Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissions.
Dutt S; Atallah MB; Minamida Y; Filatenkov A; Jensen KP; Iliopoulou BP; Tamosiuniene R; Waters J; Engleman EG; Strober S
Blood Adv; 2018 Oct; 2(19):2568-2580. PubMed ID: 30301812
[TBL] [Abstract][Full Text] [Related]
39. Unconventional T Cell Targets for Cancer Immunotherapy.
Godfrey DI; Le Nours J; Andrews DM; Uldrich AP; Rossjohn J
Immunity; 2018 Mar; 48(3):453-473. PubMed ID: 29562195
[TBL] [Abstract][Full Text] [Related]
40. Paxillin Binding to the Cytoplasmic Domain of CD103 Promotes Cell Adhesion and Effector Functions for CD8
Gauthier L; Corgnac S; Boutet M; Gros G; Validire P; Bismuth G; Mami-Chouaib F
Cancer Res; 2017 Dec; 77(24):7072-7082. PubMed ID: 29021139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
